Trial Profile
A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (≥ 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms WIP
- Sponsors Merck Sharp & Dohme
- 27 Oct 2017 Results of a sub-analysis assessing discontinuation patterns of raltegravir due to AEs, presented at the 16th European AIDS Conference
- 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Apr 2014 Planned End Date changed from 1 Jun 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.